Spotlight On... Contract manufacturer PCT will handle TxCell production in U.S.; India's Anuh Pharma has products banned by EU; BioCon hooks up with Mexico's PISA on insulin; and more...

French biotech TxCell, which had its clinical supply plant in France shut down last year by regulators there because of mold issues, has picked contract manufacturer PCT to handle its clinical supply manufacturing in the U.S. TxCell, which is working on T cell treatments for chronic inflammatory and autoimmune diseases, hired Belgian CMO MaSTherCell last year to take on its clinical supplies and potentially commercial manufacturing for its lead candidate after regulatory concerns forced TxCell to temporarily halt production at its pilot facility in Besançon, France, last June. Release (PDF) | More

> Indian drugmaker Anuh Pharma reported that after an inspection of its manufacturing site at Boisar in Maharashtra, the European Directorate for the Quality of Medicines and Healthcare (EQDM) suspended its manufacture of three erythromycin drugs. Report

> Japan's Sanova and Eisai are discontinuing the production and sales of the egg white lysozyme preparation Neuzym products used to treat conditions like chronic sinusitis, bronchitis in some countries after regulators in Japan decided that its medical usefulness has decreased. Report (PDF)

> India's BioCon has a new deal in which it will use the NAFTA benefits and supply chain of Mexico's PiSA to supply recombinant human insulin to the U.S. Report

Suggested Articles

Drugmakers have voluntarily recalled their generic Zantac from the U.S. market after the FDA raised concerns, but it has not been without a cost.

Just weeks after selling the sterile manufacturing assets of its Kyowa operation in Japan, it has unloaded the rest of its Kyowa drugmaking operation.

India’s Aurobindo, which has yet to close its $1 billion deal to buy 300 Sandoz products in the U.S., continues to rack up FDA issues.